Glycemicon

Glycemicon is a Swiss private biotechnology company developing nutraceutical products for metabolic disease, with an initial focus on prediabetes, diabetes, and obesity. The company is an ETH Zurich spinout and has centered its development efforts on tetrahydroxylated bile acids, particularly THBA, a naturally occurring bile acid found in humans and some food products. Glycemicon has described THBA as a compound that modifies adipose tissue biology to improve insulin sensitivity and support maintenance of normal blood glucose levels. Publicly available information indicates the company raised an early Series A round and planned first-in-human work in prediabetes, but there is limited evidence of a broader late-stage clinical pipeline or commercial product launch. Overall, Glycemicon appears to be a small, privately held metabolic-health company operating at an early development stage around a bile-acid-based nutraceutical concept.